Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Down 93.5% in April

Posted by Casey Walker on Apr 27th, 2024

Windtree Therapeutics, Inc. (NASDAQ:WINT – Get Free Report) was the recipient of a large decline in short interest in April. As of April 15th, there was short interest totalling 2,600 shares, a decline of 93.5% from the March 31st total of 39,700 shares. Based on an average daily volume of 15,600 shares, the short-interest ratio is presently 0.2 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “neutral” rating on shares of Windtree Therapeutics in a research note on Wednesday, January 3rd.

Get Our Latest Stock Report on WINT

Windtree Therapeutics Stock Up 3.2 %

Shares of NASDAQ:WINT opened at $5.23 on Friday. The firm has a market capitalization of $1.50 million, a P/E ratio of -0.04 and a beta of 0.61. The company has a debt-to-equity ratio of 4.42, a quick ratio of 1.35 and a current ratio of 1.35. The stock has a 50 day moving average price of $6.52 and a 200-day moving average price of $11.52. Windtree Therapeutics has a 52-week low of $4.78 and a 52-week high of $35.10.

Windtree Therapeutics (NASDAQ:WINT – Get Free Report) last announced its quarterly earnings data on Tuesday, April 16th. The company reported ($13.31) EPS for the quarter. As a group, equities research analysts anticipate that Windtree Therapeutics will post -24.93 EPS for the current fiscal year.

Windtree Therapeutics Company Profile

(Get Free Report)

Windtree Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure.